Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HIKMA Pharmaceuticals PLC Director's Dealing 2019

Mar 18, 2019

4841_dirs_2019-03-18_f6f30c57-79a1-41ee-b264-50baa2f5a9e7.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2004T

Hikma Pharmaceuticals Plc

18 March 2019

Hikma Pharmaceuticals PLC - EIP Awards

LONDON, 18 March 2019: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 17 March 2016 under the 2014 Executive Incentive Plan ("EIP") which was completed on 18 March 2019. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the EIP is £nil.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Said Darwazah
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from vesting of the conditional awards on

18 March 2019 under the 2014 EIP.
c) Price(s) and volume(s) Price(s): £nil

Volume(s): 45,100
d) Aggregated information N/A
e) Date of the transaction 18 March 2019
f) Place of the transaction London Stock Exchange (XLON)

Mazen Darwazah

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Mazen Darwazah
2 Reason for the notification
a) Position/status Executive Vice Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from vesting of the conditional awards on

18 March 2019 under the 2014 EIP.
c) Price(s) and volume(s) Price(s): £nil

Volume(s): 25,406
d) Aggregated information N/A
e) Date of the transaction 18 March 2019
f) Place of the transaction London Stock Exchange (XLON)

Bassam Kanaan

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Bassam Kanaan
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from vesting of the conditional awards on

18 March 2019 under the 2014 EIP.
c) Price(s) and volume(s) Price(s): £nil

Volume(s): 26,090
d) Aggregated information N/A
e) Date of the transaction 18 March 2019
f) Place of the transaction London Stock Exchange (XLON)

Khalid Nabilsi

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Khalid Nabilsi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from vesting of the conditional awards on

18 March 2019 under the 2014 EIP.
c) Price(s) and volume(s) Price(s): £nil

Volume(s): 20,400
d) Aggregated information N/A
e) Date of the transaction 18 March 2019
f) Place of the transaction London Stock Exchange (XLON)

Majda Labadi

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Majda Labadi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from vesting of the conditional awards on

18 March 2019 under the 2014 EIP.
c) Price(s) and volume(s) Price(s): £nil

Volume(s): 14,530
d) Aggregated information N/A
e) Date of the transaction 18 March 2019
f) Place of the transaction London Stock Exchange (XLON)

Riad Mishlawi

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Riad Mishlawi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from vesting of the conditional awards on

18 March 2019 under the 2014 EIP.
c) Price(s) and volume(s) Price(s): £nil

Volume(s): 19,890
d) Aggregated information N/A
e) Date of the transaction 18 March 2019
f) Place of the transaction London Stock Exchange (XLON)

Peter Speirs

Company Secretary, responsible for releasing this announcement

+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHBUGDXIGBBGCI